{"protocolSection":{"identificationModule":{"nctId":"NCT02623725","orgStudyIdInfo":{"id":"CYD64"},"secondaryIdInfos":[{"id":"U1111-1161-2855","type":"OTHER","domain":"WHO"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule","officialTitle":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America"},"statusModule":{"statusVerifiedDate":"2022-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-04-14","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-11-23","type":"ACTUAL"},"completionDateStruct":{"date":"2018-10-28","type":"ACTUAL"},"studyFirstSubmitDate":"2015-12-03","studyFirstSubmitQcDate":"2015-12-03","studyFirstPostDateStruct":{"date":"2015-12-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-05-24","resultsFirstSubmitQcDate":"2019-05-24","resultsFirstPostDateStruct":{"date":"2019-06-14","type":"ACTUAL"},"dispFirstSubmitDate":"2017-11-16","dispFirstSubmitQcDate":"2017-11-16","dispFirstPostDateStruct":{"date":"2017-11-20","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-03-15","lastUpdatePostDateStruct":{"date":"2022-03-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi Pasteur, a Sanofi Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The aim of the study was to assess and describe the booster effect of a CYD dengue vaccine dose administered 4 to 5 years after the completion of a 3-dose vaccination schedule.\n\nPrimary Objective\n\n\\- To demonstrate the non-inferiority, in terms of geometric mean of titer ratios (GMTRs), of a CYD dengue vaccine booster compared to the third CYD dengue vaccine injection in participants from CYD13 - NCT00993447 and CYD30 - NCT01187433 trials (participants from Group 1 only).\n\nSecondary Objectives:\n\n* If the primary objective of non-inferiority was achieved: To demonstrate the superiority, in terms of GMTRs, of a CYD dengue vaccine booster compared to the third CYD dengue vaccine injection in participants from CYD13 and CYD30 trials.\n* To describe the immune responses elicited by a CYD dengue vaccine booster and placebo injection in participants who received 3 doses of the CYD dengue vaccine in the CYD13 and CYD30 trials in all participants.\n* To describe the neutralizing antibody levels of each dengue serotype post-dose 3 (CYD13 and CYD30 participants) and immediately prior to booster or placebo injection in all participants.\n* To describe the neutralizing antibody persistence 6 months, 1 year, and 2 years post booster or placebo injection in all participants.\n* To evaluate the safety of booster vaccination with the CYD dengue vaccine in all participants.","detailedDescription":"Healthy adolescents and adults who received 3 doses of the tetravalent dengue vaccine 4 to 5 years earlier in previous CYD dengue vaccine trials (CYD13 and CYD30) received either a booster dose CYD dengue vaccine or a placebo on Day 0. They were evaluated for safety and antibody persistence of the booster injection up to 2 years post-vaccination."},"conditionsModule":{"conditions":["Dengue Fever","Dengue Hemorrhagic Fever"],"keywords":["Dengue Fever","Dengue virus","Dengue Hemorrhagic Fever","CYD Dengue Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"An observer-blind procedure was followed for the injection of the CYD Dengue Vaccine booster or placebo. Neither the observer Investigator, nor the Sponsor, nor the participant/participants' parent(s)/legally acceptable representative(s) knew which product was administered.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":251,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"CYD Dengue Vaccine Booster Group","type":"EXPERIMENTAL","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).","interventionNames":["Biological: CYD Dengue Vaccine (5-dose formulation)"]},{"label":"Placebo Group","type":"EXPERIMENTAL","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).","interventionNames":["Biological: Placebo, NaCl 0.9%"]}],"interventions":[{"type":"BIOLOGICAL","name":"CYD Dengue Vaccine (5-dose formulation)","description":"0.5 mL, Subcutaneous","armGroupLabels":["CYD Dengue Vaccine Booster Group"]},{"type":"BIOLOGICAL","name":"Placebo, NaCl 0.9%","description":"0.5 mL, Subcutaneous","armGroupLabels":["Placebo Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group","description":"Geometric Mean Titers (GMTs) of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the plaque reduction neutralization test (PRNT).","timeFrame":"28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64"}],"secondaryOutcomes":[{"measure":"GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.","timeFrame":"28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64"},{"measure":"GMTs of Antibodies Against Each Dengue Virus Serotype Before And Following Booster Injection (Inj.) With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.","timeFrame":"Pre-booster injection (Day 0) and 28 days post-booster injection"},{"measure":"GMTRs of Antibodies Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT. GMTRs were calculated as the ratio of GMTs post-booster injection and pre-booster injection.","timeFrame":"Pre-booster injection (Day 0) and 28 days post-booster injection"},{"measure":"Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers greater than or equal to (\\>=)10 (1/dilution).","timeFrame":"Pre-booster injection (Day 0) and 28 days post-booster injection"},{"measure":"Percentage of Participants With Seroconversion Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Seroconversion for each serotype was defined as the percentage of participants with either a pre-booster titer \\<10 (1/dilution) and a post-booster titer \\>=40 (1/dilution), or a pre-booster titer \\>=10 (1/dilution) and a \\>=4-fold increase in post-booster titer as determined by PRNT.","timeFrame":"28 days post-booster injection"},{"measure":"GMTs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the PRNT.","timeFrame":"28 days post-dose 3 in CYD13 or CYD30 and pre-booster injection (Day 0) in CYD64"},{"measure":"GMTRs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the PRNT. GMTRs were calculated as the ratio of GMTs pre-booster injection and post-dose injection.","timeFrame":"28 days post-dose 3 in CYD13 or CYD30 and pre-booster injection (Day 0) in CYD64"},{"measure":"Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers \\>=10 (1/dilution).","timeFrame":"28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64"},{"measure":"GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.","timeFrame":"6 months,12 months, and 24 months post-booster injection in CYD64"},{"measure":"GMTRs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT. GMTRs were calculated as the ratio of GMTs post-booster injection and pre-booster injection.","timeFrame":"Pre-booster injection (Day 0), 6 months, 12 months, and 24 months post-booster injection in CYD64"},{"measure":"Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers \\>=10 (1/dilution).","timeFrame":"6 months,12 months, and 24 months post-booster injection in CYD64"},{"measure":"Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions: Pain: significant; prevents daily activity; Erythema and Swelling: \\>100 millimeters (mm).","timeFrame":"Within 7 days after booster injection"},{"measure":"Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever: \\>=39°C; Headache, Malaise, Myalgia, and Asthenia: significant, prevents daily activity.","timeFrame":"Within 14 days after booster injection"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Had been identified as a potential participant by the Sponsor and is included in the list provided to the Investigator (i.e., aged 9 to 16 years on the day of first vaccination of CYD dengue vaccine in CYD13/CYD30 and has a post-dose 3 serum sample available \\[at least 400 microliters of serum\\]).\n* Participants were in good health, based on medical history and physical examination.\n* Assent form or informed consent form (ICF) had been signed and dated by the participant (based on local regulations), and ICF had been signed and dated by the parent(s) or another legally acceptable representative (and by an independent witness if required by local regulations).\n* Participant and parent(s)/legally acceptable representative(s) attended all scheduled visits and complied with all trial procedures.\n\nExclusion Criteria:\n\n* Participant who received any other dengue vaccination that was not part of the CYD13 or CYD30 trials.\n* Participant was pregnant, or lactating, or of childbearing potential (to be considered of non childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination).\n* Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.\n* Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine in the 4 weeks following the trial vaccination.\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months.\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.\n* Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion.\n* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response.\n* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.\n* Current alcohol abuse or drug addiction.\n* Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature \\>= 38.0°C). A prospective participant should not be included in the study until the condition had resolved or the febrile event had subsided.\n* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"13 Years","maximumAge":"22 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Sanofi Pasteur Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Investigational Site Number 001","city":"Vitória","zip":"29040-091","country":"Brazil","geoPoint":{"lat":-20.31944,"lon":-40.33778}},{"facility":"Investigational Site Number 002","city":"Bucaramanga","country":"Colombia","geoPoint":{"lat":7.125,"lon":-73.11895}},{"facility":"Investigational Site Number 003","city":"Tegucigalpa","country":"Honduras","geoPoint":{"lat":14.0818,"lon":-87.20681}},{"facility":"Investigational Site Number 004","city":"Temixco","zip":"62587","country":"Mexico","geoPoint":{"lat":18.84578,"lon":-99.22367}},{"facility":"Investigational Site Number 005","city":"Carolina","zip":"984","country":"Puerto Rico","geoPoint":{"lat":18.38078,"lon":-65.95739}}]},"referencesModule":{"references":[{"pmid":"30986790","type":"DERIVED","citation":"Coronel D, Garcia-Rivera EJ, Rivera M, Arredondo-Garcia JL, Dietze R, Perroud AP, Cortes M, Bonaparte M, Zhao J, Tila M, Jackson N, Zambrano B, Noriega F. Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule. Pediatr Infect Dis J. 2019 May;38(5):e90-e95. doi: 10.1097/INF.0000000000002286."}],"seeAlsoLinks":[{"label":"Related Info","url":"http://www.sanofipasteur.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 251 participants who received 3 doses of CYD dengue vaccine in previous studies CYD13 (NCT00993447) and CYD30 (NCT01187433) were enrolled and randomized in this study (CYD64).","recruitmentDetails":"Study participants were enrolled from 14 April 2016 to 19 October 2016 at 5 sites, one each in Brazil, Colombia, Honduras, Mexico, and Puerto Rico.","groups":[{"id":"FG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"FG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"187"},{"groupId":"FG001","numSubjects":"64"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"171"},{"groupId":"FG001","numSubjects":"58"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"6"}]}],"dropWithdraws":[{"type":"Non compliance with protocol","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Serious adverse event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis was performed on all randomized participants.","groups":[{"id":"BG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"BG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"187"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"251"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"82"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"124"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"169"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19.2","spread":"2.14"},{"groupId":"BG001","value":"19.0","spread":"1.99"},{"groupId":"BG002","value":"19.1","spread":"2.10"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"116"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"135"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group","description":"Geometric Mean Titers (GMTs) of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the plaque reduction neutralization test (PRNT).","populationDescription":"Analysis was performed on Per-Protocol Analysis Set which included all participants who had no protocol deviations from the present study (CYD64). Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers (1/dilution)","timeFrame":"28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group:Post Dose 3 in CYD13 or CYD30","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30) were included in this study (CYD64)."},{"id":"OG001","title":"CYD Dengue Vaccine Booster Group: Post Booster Dose in CYD64","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"177"}]}],"classes":[{"title":"Dengue Virus Serotype 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"177"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"316","lowerLimit":"233","upperLimit":"428"},{"groupId":"OG001","value":"560","lowerLimit":"421","upperLimit":"744"}]}]},{"title":"Dengue Virus Serotype 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"177"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"356","lowerLimit":"275","upperLimit":"462"},{"groupId":"OG001","value":"657","lowerLimit":"520","upperLimit":"830"}]}]},{"title":"Dengue Virus Serotype 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"177"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"640","lowerLimit":"516","upperLimit":"794"},{"groupId":"OG001","value":"671","lowerLimit":"535","upperLimit":"843"}]}]},{"title":"Dengue Virus Serotype 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"177"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"243","lowerLimit":"195","upperLimit":"303"},{"groupId":"OG001","value":"344","lowerLimit":"279","upperLimit":"424"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 1","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The overall non-inferiority of the booster dose was to be demonstrated if the lower limit of the two-sided 95 percent (%) Confidence Interval (CI) of the Geometric mean of titer ratios (GMTRs) (booster vs post-dose 3) was greater than (\\>) 1/2 for each serotype.","paramType":"Geometric mean of titer ratio","paramValue":"1.66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.33","ciUpperLimit":"2.06"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 2","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The overall non-inferiority of the booster dose was to be demonstrated if the lower limit of the two-sided 95% CI of the GMTRs (booster vs post-dose 3) was \\>1/2 for each serotype.","paramType":"Geometric mean of titer ratio","paramValue":"1.82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.43","ciUpperLimit":"2.31"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 3","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The overall non-inferiority of the booster dose was to be demonstrated if the lower limit of the two-sided 95% CI of the GMTRs (booster vs post-dose 3) was \\>1/2 for each serotype.","paramType":"Geometric mean of titer ratio","paramValue":"1.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.841","ciUpperLimit":"1.27"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 4","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The overall non-inferiority of the booster dose was to be demonstrated if the lower limit of the two-sided 95% CI of the GMTRs (booster vs post-dose 3) was \\>1/2 for each serotype.","paramType":"Geometric mean of titer ratio","paramValue":"1.32","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.01","ciUpperLimit":"1.74"}]},{"type":"SECONDARY","title":"GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.","populationDescription":"Analysis was performed on Full analysis set which included all participants who received either CYD Dengue Vaccine or placebo and had blood sample drawn and valid post-injection serology results. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers (1/dilution)","timeFrame":"28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group:Post Dose 3 in CYD13 or CYD30","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30) were included in this study (CYD64)."},{"id":"OG001","title":"CYD Dengue Vaccine Booster Group: Post Booster Dose in CYD64","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"184"}]}],"classes":[{"title":"Dengue Virus Serotype 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"304","lowerLimit":"225","upperLimit":"409"},{"groupId":"OG001","value":"538","lowerLimit":"406","upperLimit":"714"}]}]},{"title":"Dengue Virus Serotype 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"338","lowerLimit":"261","upperLimit":"436"},{"groupId":"OG001","value":"648","lowerLimit":"515","upperLimit":"817"}]}]},{"title":"Dengue Virus Serotype 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"617","lowerLimit":"499","upperLimit":"762"},{"groupId":"OG001","value":"660","lowerLimit":"528","upperLimit":"827"}]}]},{"title":"Dengue Virus Serotype 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"241","lowerLimit":"195","upperLimit":"298"},{"groupId":"OG001","value":"341","lowerLimit":"278","upperLimit":"418"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 1","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The superiority was to be demonstrated if the lower limit of the two-sided 95% CI for the ratio was \\>1.","paramType":"Geometric mean of titer ratio","paramValue":"1.66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.34","ciUpperLimit":"2.05"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 2","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The superiority was to be demonstrated if the lower limit of the two-sided 95% CI for the ratio was \\>1.","paramType":"Geometric mean of titer ratio","paramValue":"1.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.49","ciUpperLimit":"2.41"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 3","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The superiority was to be demonstrated if the lower limit of the two-sided 95% CI for the ratio was \\>1.","paramType":"Geometric mean of titer ratio","paramValue":"1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.860","ciUpperLimit":"1.30"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 4","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The superiority was to be demonstrated if the lower limit of the two-sided 95% CI for the ratio was \\>1.","paramType":"Geometric mean of titer ratio","paramValue":"1.33","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.02","ciUpperLimit":"1.73"}]},{"type":"SECONDARY","title":"GMTs of Antibodies Against Each Dengue Virus Serotype Before And Following Booster Injection (Inj.) With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.","populationDescription":"Analysis was performed on Per-Protocol Analysis Set.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers (1/dilution)","timeFrame":"Pre-booster injection (Day 0) and 28 days post-booster injection","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Dengue Virus Serotype 1: Pre-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"325","lowerLimit":"233","upperLimit":"452"},{"groupId":"OG001","value":"349","lowerLimit":"201","upperLimit":"607"}]}]},{"title":"Dengue Virus Serotype 1: 28 days Post-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"560","lowerLimit":"421","upperLimit":"744"},{"groupId":"OG001","value":"297","lowerLimit":"162","upperLimit":"547"}]}]},{"title":"Dengue Virus Serotype 2: Pre-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"360","lowerLimit":"267","upperLimit":"484"},{"groupId":"OG001","value":"323","lowerLimit":"195","upperLimit":"535"}]}]},{"title":"Dengue Virus Serotype 2: 28 days Post-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"657","lowerLimit":"520","upperLimit":"830"},{"groupId":"OG001","value":"354","lowerLimit":"205","upperLimit":"610"}]}]},{"title":"Dengue Virus Serotype 3: Pre-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"357","lowerLimit":"269","upperLimit":"472"},{"groupId":"OG001","value":"442","lowerLimit":"270","upperLimit":"724"}]}]},{"title":"Dengue Virus Serotype 3: 28 days Post-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"671","lowerLimit":"535","upperLimit":"843"},{"groupId":"OG001","value":"432","lowerLimit":"266","upperLimit":"700"}]}]},{"title":"Dengue Virus Serotype 4: Pre-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"162","lowerLimit":"134","upperLimit":"195"},{"groupId":"OG001","value":"161","lowerLimit":"108","upperLimit":"242"}]}]},{"title":"Dengue Virus Serotype 4: 28 days Post-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"344","lowerLimit":"279","upperLimit":"424"},{"groupId":"OG001","value":"161","lowerLimit":"110","upperLimit":"237"}]}]}]},{"type":"SECONDARY","title":"GMTRs of Antibodies Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT. GMTRs were calculated as the ratio of GMTs post-booster injection and pre-booster injection.","populationDescription":"Analysis was performed on Per-Protocol Analysis Set.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Pre-booster injection (Day 0) and 28 days post-booster injection","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Dengue Virus Serotype 1","categories":[{"measurements":[{"groupId":"OG000","value":"1.59","lowerLimit":"1.33","upperLimit":"1.90"},{"groupId":"OG001","value":"0.798","lowerLimit":"0.623","upperLimit":"1.02"}]}]},{"title":"Dengue Virus Serotype 2","categories":[{"measurements":[{"groupId":"OG000","value":"1.70","lowerLimit":"1.43","upperLimit":"2.03"},{"groupId":"OG001","value":"1.03","lowerLimit":"0.754","upperLimit":"1.40"}]}]},{"title":"Dengue Virus Serotype 3","categories":[{"measurements":[{"groupId":"OG000","value":"1.78","lowerLimit":"1.47","upperLimit":"2.16"},{"groupId":"OG001","value":"0.946","lowerLimit":"0.749","upperLimit":"1.19"}]}]},{"title":"Dengue Virus Serotype 4","categories":[{"measurements":[{"groupId":"OG000","value":"2.09","lowerLimit":"1.65","upperLimit":"2.63"},{"groupId":"OG001","value":"0.946","lowerLimit":"0.777","upperLimit":"1.15"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers greater than or equal to (\\>=)10 (1/dilution).","populationDescription":"Analysis was performed on Per-Protocol Analysis Set.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster injection (Day 0) and 28 days post-booster injection","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Dengue Virus Serotype 1: Pre-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"88.1"},{"groupId":"OG001","value":"90.6"}]}]},{"title":"Dengue Virus Serotype 1: 28 days Post-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"96.0"},{"groupId":"OG001","value":"84.4"}]}]},{"title":"Dengue Virus Serotype 2: Pre-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"89.8"},{"groupId":"OG001","value":"90.6"}]}]},{"title":"Dengue Virus Serotype 2: 28 days Post-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"98.9"},{"groupId":"OG001","value":"87.5"}]}]},{"title":"Dengue Virus Serotype 3: Pre-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"92.1"},{"groupId":"OG001","value":"95.3"}]}]},{"title":"Dengue Virus Serotype 3: 28 days Post-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"95.3"}]}]},{"title":"Dengue Virus Serotype 4: Pre-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"97.2"},{"groupId":"OG001","value":"92.2"}]}]},{"title":"Dengue Virus Serotype 4: 28 days Post-booster Inj.","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"93.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Seroconversion for each serotype was defined as the percentage of participants with either a pre-booster titer \\<10 (1/dilution) and a post-booster titer \\>=40 (1/dilution), or a pre-booster titer \\>=10 (1/dilution) and a \\>=4-fold increase in post-booster titer as determined by PRNT.","populationDescription":"Analysis was performed on Full analysis set. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"28 days post-booster injection","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Dengue Virus Serotype 1","categories":[{"measurements":[{"groupId":"OG000","value":"17.9"},{"groupId":"OG001","value":"3.1"}]}]},{"title":"Dengue Virus Serotype 2","categories":[{"measurements":[{"groupId":"OG000","value":"20.1"},{"groupId":"OG001","value":"17.2"}]}]},{"title":"Dengue Virus Serotype 3","categories":[{"measurements":[{"groupId":"OG000","value":"21.2"},{"groupId":"OG001","value":"4.7"}]}]},{"title":"Dengue Virus Serotype 4","categories":[{"measurements":[{"groupId":"OG000","value":"20.7"},{"groupId":"OG001","value":"6.3"}]}]}]},{"type":"SECONDARY","title":"GMTs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the PRNT.","populationDescription":"Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers (1/dilution)","timeFrame":"28 days post-dose 3 in CYD13 or CYD30 and pre-booster injection (Day 0) in CYD64","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Dengue Virus Serotype 1: 28 days Post-dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"316","lowerLimit":"233","upperLimit":"428"},{"groupId":"OG001","value":"232","lowerLimit":"142","upperLimit":"381"}]}]},{"title":"Dengue Virus Serotype 1: Pre-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"325","lowerLimit":"233","upperLimit":"452"},{"groupId":"OG001","value":"349","lowerLimit":"201","upperLimit":"607"}]}]},{"title":"Dengue Virus Serotype 2: 28 days Post-dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"356","lowerLimit":"275","upperLimit":"462"},{"groupId":"OG001","value":"303","lowerLimit":"210","upperLimit":"438"}]}]},{"title":"Dengue Virus Serotype 2: Pre-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"360","lowerLimit":"267","upperLimit":"484"},{"groupId":"OG001","value":"323","lowerLimit":"195","upperLimit":"535"}]}]},{"title":"Dengue Virus Serotype 3: 28 days Post-dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"640","lowerLimit":"516","upperLimit":"794"},{"groupId":"OG001","value":"541","lowerLimit":"372","upperLimit":"785"}]}]},{"title":"Dengue Virus Serotype 3: Pre-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"357","lowerLimit":"269","upperLimit":"472"},{"groupId":"OG001","value":"442","lowerLimit":"270","upperLimit":"724"}]}]},{"title":"Dengue Virus Serotype 4: 28 days Post-dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"243","lowerLimit":"195","upperLimit":"303"},{"groupId":"OG001","value":"255","lowerLimit":"192","upperLimit":"340"}]}]},{"title":"Dengue Virus Serotype 4: Pre-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"162","lowerLimit":"134","upperLimit":"195"},{"groupId":"OG001","value":"161","lowerLimit":"108","upperLimit":"242"}]}]}]},{"type":"SECONDARY","title":"GMTRs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the PRNT. GMTRs were calculated as the ratio of GMTs pre-booster injection and post-dose injection.","populationDescription":"Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed'=participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"28 days post-dose 3 in CYD13 or CYD30 and pre-booster injection (Day 0) in CYD64","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Dengue Virus Serotype 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.952","lowerLimit":"0.765","upperLimit":"1.18"},{"groupId":"OG001","value":"1.41","lowerLimit":"0.927","upperLimit":"2.14"}]}]},{"title":"Dengue Virus Serotype 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.986","lowerLimit":"0.778","upperLimit":"1.25"},{"groupId":"OG001","value":"1.04","lowerLimit":"0.662","upperLimit":"1.65"}]}]},{"title":"Dengue Virus Serotype 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.536","lowerLimit":"0.440","upperLimit":"0.654"},{"groupId":"OG001","value":"0.818","lowerLimit":"0.574","upperLimit":"1.16"}]}]},{"title":"Dengue Virus Serotype 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.618","lowerLimit":"0.497","upperLimit":"0.770"},{"groupId":"OG001","value":"0.613","lowerLimit":"0.427","upperLimit":"0.881"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers \\>=10 (1/dilution).","populationDescription":"Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Dengue Virus Serotype 1: 28 days Post-dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.9"},{"groupId":"OG001","value":"90.6"}]}]},{"title":"Dengue Virus Serotype 1: 28 days Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.0"},{"groupId":"OG001","value":"84.4"}]}]},{"title":"Dengue Virus Serotype 2: 28 days Post-dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.4"},{"groupId":"OG001","value":"96.9"}]}]},{"title":"Dengue Virus Serotype 2: 28 days Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.9"},{"groupId":"OG001","value":"87.5"}]}]},{"title":"Dengue Virus Serotype 3: 28 days Post-dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Dengue Virus Serotype 3: 28 days Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"95.3"}]}]},{"title":"Dengue Virus Serotype 4: 28 days Post-dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.0"},{"groupId":"OG001","value":"96.8"}]}]},{"title":"Dengue Virus Serotype 4: 28 days Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"93.8"}]}]}]},{"type":"SECONDARY","title":"GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.","populationDescription":"Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers (1/dilution)","timeFrame":"6 months,12 months, and 24 months post-booster injection in CYD64","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Dengue Virus Serotype 1:6 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"270","lowerLimit":"205","upperLimit":"356"},{"groupId":"OG001","value":"192","lowerLimit":"111","upperLimit":"329"}]}]},{"title":"Dengue Virus Serotype1:12 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"270","lowerLimit":"205","upperLimit":"356"},{"groupId":"OG001","value":"185","lowerLimit":"112","upperLimit":"304"}]}]},{"title":"Dengue Virus Serotype1:24 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"241","lowerLimit":"180","upperLimit":"323"},{"groupId":"OG001","value":"182","lowerLimit":"112","upperLimit":"297"}]}]},{"title":"Dengue Virus Serotype 2:6 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"442","lowerLimit":"358","upperLimit":"546"},{"groupId":"OG001","value":"335","lowerLimit":"217","upperLimit":"515"}]}]},{"title":"Dengue Virus Serotype2:12 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"269","lowerLimit":"217","upperLimit":"335"},{"groupId":"OG001","value":"225","lowerLimit":"152","upperLimit":"334"}]}]},{"title":"Dengue Virus Serotype2:24 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"246","lowerLimit":"192","upperLimit":"315"},{"groupId":"OG001","value":"187","lowerLimit":"126","upperLimit":"279"}]}]},{"title":"Dengue Virus Serotype 3:6 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"503","lowerLimit":"397","upperLimit":"636"},{"groupId":"OG001","value":"447","lowerLimit":"285","upperLimit":"701"}]}]},{"title":"Dengue Virus Serotype3:12 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"303","lowerLimit":"242","upperLimit":"379"},{"groupId":"OG001","value":"328","lowerLimit":"219","upperLimit":"491"}]}]},{"title":"Dengue Virus Serotype3:24 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"341","lowerLimit":"275","upperLimit":"423"},{"groupId":"OG001","value":"309","lowerLimit":"194","upperLimit":"492"}]}]},{"title":"Dengue Virus Serotype 4:6 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"233","lowerLimit":"198","upperLimit":"273"},{"groupId":"OG001","value":"156","lowerLimit":"115","upperLimit":"212"}]}]},{"title":"Dengue Virus Serotype4:12 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"169","lowerLimit":"144","upperLimit":"199"},{"groupId":"OG001","value":"127","lowerLimit":"96.3","upperLimit":"167"}]}]},{"title":"Dengue Virus Serotype4:24 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"150","lowerLimit":"129","upperLimit":"174"},{"groupId":"OG001","value":"114","lowerLimit":"85.2","upperLimit":"153"}]}]}]},{"type":"SECONDARY","title":"GMTRs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT. GMTRs were calculated as the ratio of GMTs post-booster injection and pre-booster injection.","populationDescription":"Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Pre-booster injection (Day 0), 6 months, 12 months, and 24 months post-booster injection in CYD64","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Dengue Virus Serotype 1: Month 6/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.763","lowerLimit":"0.643","upperLimit":"0.904"},{"groupId":"OG001","value":"0.502","lowerLimit":"0.364","upperLimit":"0.693"}]}]},{"title":"Dengue Virus Serotype 1: Month 12/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.722","lowerLimit":"0.607","upperLimit":"0.859"},{"groupId":"OG001","value":"0.483","lowerLimit":"0.366","upperLimit":"0.638"}]}]},{"title":"Dengue Virus Serotype 1: Month 24/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.642","lowerLimit":"0.532","upperLimit":"0.774"},{"groupId":"OG001","value":"0.509","lowerLimit":"0.382","upperLimit":"0.678"}]}]},{"title":"Dengue Virus Serotype 2: Month 6/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","lowerLimit":"0.922","upperLimit":"1.40"},{"groupId":"OG001","value":"0.998","lowerLimit":"0.716","upperLimit":"1.39"}]}]},{"title":"Dengue Virus Serotype 2: Month 12/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.651","lowerLimit":"0.539","upperLimit":"0.786"},{"groupId":"OG001","value":"0.630","lowerLimit":"0.460","upperLimit":"0.863"}]}]},{"title":"Dengue Virus Serotype 2: Month 24/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.579","lowerLimit":"0.473","upperLimit":"0.709"},{"groupId":"OG001","value":"0.548","lowerLimit":"0.373","upperLimit":"0.806"}]}]},{"title":"Dengue Virus Serotype 3: Month 6/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","lowerLimit":"1.09","upperLimit":"1.65"},{"groupId":"OG001","value":"0.957","lowerLimit":"0.701","upperLimit":"1.31"}]}]},{"title":"Dengue Virus Serotype 3: Month 12/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.786","lowerLimit":"0.652","upperLimit":"0.947"},{"groupId":"OG001","value":"0.667","lowerLimit":"0.505","upperLimit":"0.883"}]}]},{"title":"Dengue Virus Serotype 3: Month 24/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.878","lowerLimit":"0.749","upperLimit":"1.03"},{"groupId":"OG001","value":"0.682","lowerLimit":"0.523","upperLimit":"0.890"}]}]},{"title":"Dengue Virus Serotype 4: Month 6/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","lowerLimit":"1.17","upperLimit":"1.72"},{"groupId":"OG001","value":"0.912","lowerLimit":"0.691","upperLimit":"1.20"}]}]},{"title":"Dengue Virus Serotype 4: Month 12/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","lowerLimit":"0.846","upperLimit":"1.22"},{"groupId":"OG001","value":"0.709","lowerLimit":"0.553","upperLimit":"0.909"}]}]},{"title":"Dengue Virus Serotype 4: Month 24/Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.890","lowerLimit":"0.753","upperLimit":"1.05"},{"groupId":"OG001","value":"0.684","lowerLimit":"0.534","upperLimit":"0.877"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers \\>=10 (1/dilution).","populationDescription":"Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"6 months,12 months, and 24 months post-booster injection in CYD64","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Dengue Virus Serotype 1:6 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.4"},{"groupId":"OG001","value":"85.7"}]}]},{"title":"Dengue Virus Serotype1:12 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.9"},{"groupId":"OG001","value":"88.7"}]}]},{"title":"Dengue Virus Serotype1:24 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.2"},{"groupId":"OG001","value":"89.7"}]}]},{"title":"Dengue Virus Serotype 2:6 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.9"},{"groupId":"OG001","value":"92.1"}]}]},{"title":"Dengue Virus Serotype2:12 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.5"},{"groupId":"OG001","value":"91.9"}]}]},{"title":"Dengue Virus Serotype2:24 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.3"},{"groupId":"OG001","value":"91.4"}]}]},{"title":"Dengue Virus Serotype 3:6 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.7"},{"groupId":"OG001","value":"95.2"}]}]},{"title":"Dengue Virus Serotype3:12 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.1"},{"groupId":"OG001","value":"96.8"}]}]},{"title":"Dengue Virus Serotype3:24 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"94.8"}]}]},{"title":"Dengue Virus Serotype 4:6 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.9"},{"groupId":"OG001","value":"95.2"}]}]},{"title":"Dengue Virus Serotype4:12 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.6"},{"groupId":"OG001","value":"95.2"}]}]},{"title":"Dengue Virus Serotype4:24 months Post-booster Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.8"},{"groupId":"OG001","value":"94.8"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions: Pain: significant; prevents daily activity; Erythema and Swelling: \\>100 millimeters (mm).","populationDescription":"Analysis was performed on Safety Analysis Set which included all participants who received either CYD dengue vaccine or placebo.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 7 days after booster injection","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Injection-site Pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"12"}]}]},{"title":"Injection-site Pain: Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Injection-site Erythema: Any","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Injection-site Erythema: Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Injection-site Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Injection-site Swelling: Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Booster Injection With Either CYD Dengue Vaccine or Placebo","description":"Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever: \\>=39°C; Headache, Malaise, Myalgia, and Asthenia: significant, prevents daily activity.","populationDescription":"Analysis was performed on Safety Analysis Set. Here, 'number analyzed' = participants with available data for specified category.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 14 days after booster injection","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64)."},{"id":"OG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Fever: Any Grade","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"}]}]},{"title":"Fever: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Headache: Any Grade","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"22"}]}]},{"title":"Headache: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"2"}]}]},{"title":"Malaise: Any Grade","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"19"}]}]},{"title":"Malaise: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}]}]},{"title":"Myalgia: Any Grade","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"19"}]}]},{"title":"Myalgia: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Asthenia: Any Grade","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"14"}]}]},{"title":"Asthenia: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse event (AE) data was collected from Day 0 (post-vaccination) up to 28 days post-booster injection. Solicited Reaction (SR) data was collected within 7 and 14 days after vaccination. Serious adverse event (SAE) data was collected throughout the study (up to 24 months after last vaccination).","description":"Analysis was performed on Safety Analysis Set. A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination.","eventGroups":[{"id":"EG000","title":"CYD Dengue Vaccine Booster Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).","deathsNumAffected":0,"deathsNumAtRisk":187,"seriousNumAffected":19,"seriousNumAtRisk":187,"otherNumAffected":115,"otherNumAtRisk":187},{"id":"EG001","title":"Placebo Group","description":"Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).","deathsNumAffected":2,"deathsNumAtRisk":64,"seriousNumAffected":5,"seriousNumAtRisk":64,"otherNumAffected":31,"otherNumAtRisk":64}],"seriousEvents":[{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":187},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":64}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]},{"term":"Gun Shot Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":187},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":64}]},{"term":"Intentional Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]},{"term":"Road Traffic Accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]},{"term":"Toxicity To Various Agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":64}]},{"term":"Abortion","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]},{"term":"Abortion Spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":64}]},{"term":"Ectopic Pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]},{"term":"Pre-Eclampsia","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]},{"term":"Completed Suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":187},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":64}]},{"term":"Suicide Attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]},{"term":"Abortion Induced","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":187},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":64}]}],"otherEvents":[{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":52,"numAtRisk":187},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":64}]},{"term":"Injection Site Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":46,"numAtRisk":187},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":64}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":48,"numAffected":47,"numAtRisk":187},{"groupId":"EG001","numEvents":19,"numAffected":19,"numAtRisk":64}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":187},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":64}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":60,"numAtRisk":187},{"groupId":"EG001","numEvents":19,"numAffected":19,"numAtRisk":64}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":90,"numAffected":88,"numAtRisk":187},{"groupId":"EG001","numEvents":23,"numAffected":22,"numAtRisk":64}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications."},"pointOfContact":{"title":"Medical Director","organization":"Sanofi Pasteur","email":"Contact-US@sanofi.com","phone":"800-633-1610","phoneExt":"ext 1#"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D003715","term":"Dengue"},{"id":"D019595","term":"Severe Dengue"}],"ancestors":[{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D007239","term":"Infections"},{"id":"D001102","term":"Arbovirus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018177","term":"Flavivirus Infections"},{"id":"D018178","term":"Flaviviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D006482","term":"Hemorrhagic Fevers, Viral"}]},"interventionBrowseModule":{"meshes":[{"id":"D004304","term":"Dosage Forms"},{"id":"D012965","term":"Sodium Chloride"}],"ancestors":[{"id":"D004364","term":"Pharmaceutical Preparations"},{"id":"D013678","term":"Technology, Pharmaceutical"},{"id":"D008919","term":"Investigative Techniques"},{"id":"D002712","term":"Chlorides"},{"id":"D006851","term":"Hydrochloric Acid"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017670","term":"Sodium Compounds"}]}},"hasResults":true}